Share Price and Basic Stock Data
Last Updated: December 9, 2025, 6:28 pm
| PEG Ratio | 0.98 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Choksi Laboratories Ltd operates in the medical research services sector, an area increasingly vital in today’s healthcare landscape. The company reported a revenue of ₹34.44 Cr for FY 2023, which reflects a solid growth trajectory from ₹30.04 Cr in FY 2022. This upward trend in revenue has been consistent, with projected figures for FY 2025 reaching ₹41.78 Cr. However, the quarterly sales figures exhibit some volatility, with the latest quarterly report for September 2023 standing at ₹7.95 Cr, a decrease from ₹8.88 Cr in June 2023. This fluctuation can be attributed to seasonal effects or project-based revenue, which is common in the medical services industry. The company’s ability to maintain a steady growth rate over the years suggests a robust operational framework, although the recent quarterly dip raises questions about the sustainability of this growth in the near term.
Profitability and Efficiency Metrics
Profitability metrics present a mixed picture for Choksi Laboratories. The operating profit margin (OPM) stood at a commendable 30.70% as of FY 2025, indicating strong operational efficiency. However, the net profit margin of 3.64% suggests that while the company is effective at generating revenue, its ability to convert that revenue into profit is somewhat limited. The historical context shows a peak OPM of 46.35% in March 2022, which has since declined, reflecting pressures on cost management or pricing strategies. Moreover, the company’s interest coverage ratio of 4.27x indicates it can comfortably meet its interest obligations, though the return on equity (ROE) at 6.63% reveals that shareholder returns are relatively modest compared to industry standards. This combination of strong margins but lower equity returns presents a dual narrative of operational strength tempered by profitability challenges.
Balance Sheet Strength and Financial Ratios
Choksi Laboratories’ balance sheet exhibits a mixed bag of strengths and weaknesses. The company’s total borrowings have decreased to ₹28.87 Cr, down from ₹32.41 Cr in the previous fiscal year, indicating a gradual reduction in leverage and improved financial health. However, the debt-to-equity ratio of 1.19x suggests that the company is still heavily reliant on borrowed funds, which could pose risks if interest rates rise or cash flows become unstable. On the asset side, total assets have reported a stable growth to ₹65.33 Cr, with reserves also increasing to ₹17.53 Cr, indicating the company is building a cushion for future growth. The current ratio of 0.68x, however, raises concerns about liquidity, as it falls below the ideal benchmark of 1. This could make the company vulnerable to short-term financial pressures, despite its overall asset base appearing healthy.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Choksi Laboratories reveals a stable promoter holding of 31.48%, which has remained unchanged over recent quarters. This stability can instill confidence among retail investors, as it suggests a commitment from the founders to the company’s long-term vision. However, the lack of foreign institutional investment (FIIs) until recently, with only 5.69% reported as of March 2025, may limit broader market confidence. The public shareholding, which constituted 62.83%, reflects a strong retail interest in the company, but the declining trend from previous quarters could indicate waning enthusiasm among investors. With over 4,000 shareholders, the company has a diverse base, but the concentration of public ownership could lead to volatility in stock price if sentiment shifts suddenly.
Outlook, Risks, and Final Insight
Looking ahead, Choksi Laboratories presents an intriguing investment opportunity, albeit with notable risks. The company’s strong operational margins and gradual debt reduction are positive indicators. However, the fluctuations in revenue and modest profitability metrics suggest that it may face challenges in sustaining growth momentum. Investors should be aware of the risks associated with its liquidity position and reliance on borrowed funds, particularly in an uncertain economic climate. Additionally, the lack of significant FII participation could hinder the stock’s appeal to large institutional investors. For retail investors, the key will be to monitor quarterly performance closely and assess how effectively the company manages its costs and adapts to market demands. In a sector as critical as medical research, the potential for growth remains substantial, but it will require careful navigation of the inherent risks and market dynamics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Choksi Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Choksi Laboratories Ltd | 78.2 Cr. | 112 | 237/60.2 | 47.1 | 35.2 | 0.00 % | 9.20 % | 6.63 % | 10.0 |
| Vimta Labs Ltd | 2,654 Cr. | 593 | 903/372 | 35.6 | 93.5 | 0.17 % | 25.2 % | 19.4 % | 2.00 |
| Industry Average | 2,654.00 Cr | 352.50 | 41.35 | 64.35 | 0.09% | 17.20% | 13.02% | 6.00 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.14 | 8.24 | 8.68 | 7.84 | 9.78 | 8.88 | 7.95 | 8.79 | 11.12 | 10.74 | 9.26 | 10.38 | 11.40 |
| Expenses | 5.44 | 5.95 | 6.35 | 5.61 | 6.30 | 6.45 | 5.84 | 6.55 | 7.63 | 7.91 | 6.90 | 7.84 | 7.90 |
| Operating Profit | 4.70 | 2.29 | 2.33 | 2.23 | 3.48 | 2.43 | 2.11 | 2.24 | 3.49 | 2.83 | 2.36 | 2.54 | 3.50 |
| OPM % | 46.35% | 27.79% | 26.84% | 28.44% | 35.58% | 27.36% | 26.54% | 25.48% | 31.38% | 26.35% | 25.49% | 24.47% | 30.70% |
| Other Income | 0.02 | 0.00 | 0.02 | 0.10 | 2.26 | 0.00 | 0.05 | 0.00 | 0.06 | 0.01 | 0.01 | 0.01 | 0.04 |
| Interest | 0.76 | 0.75 | 0.87 | 0.93 | 0.94 | 0.82 | 0.74 | 0.67 | 0.77 | 0.72 | 0.66 | 0.69 | 0.58 |
| Depreciation | 1.35 | 1.40 | 1.31 | 1.36 | 1.42 | 1.39 | 1.41 | 1.43 | 1.49 | 1.50 | 1.61 | 1.68 | 1.70 |
| Profit before tax | 2.61 | 0.14 | 0.17 | 0.04 | 3.38 | 0.22 | 0.01 | 0.14 | 1.29 | 0.62 | 0.10 | 0.18 | 1.26 |
| Tax % | 14.18% | -107.14% | 64.71% | 425.00% | 11.54% | -59.09% | 0.00% | 57.14% | 46.51% | 30.65% | 20.00% | 44.44% | 26.98% |
| Net Profit | 2.24 | 0.30 | 0.06 | -0.13 | 2.99 | 0.36 | 0.01 | 0.06 | 0.68 | 0.42 | 0.08 | 0.11 | 0.92 |
| EPS in Rs | 3.22 | 0.43 | 0.09 | -0.19 | 4.29 | 0.52 | 0.01 | 0.09 | 0.98 | 0.60 | 0.11 | 0.16 | 1.32 |
Last Updated: July 16, 2025, 10:25 am
Below is a detailed analysis of the quarterly data for Choksi Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 11.40 Cr.. The value appears strong and on an upward trend. It has increased from 10.38 Cr. (Dec 2024) to 11.40 Cr., marking an increase of 1.02 Cr..
- For Expenses, as of Mar 2025, the value is 7.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.84 Cr. (Dec 2024) to 7.90 Cr., marking an increase of 0.06 Cr..
- For Operating Profit, as of Mar 2025, the value is 3.50 Cr.. The value appears strong and on an upward trend. It has increased from 2.54 Cr. (Dec 2024) to 3.50 Cr., marking an increase of 0.96 Cr..
- For OPM %, as of Mar 2025, the value is 30.70%. The value appears strong and on an upward trend. It has increased from 24.47% (Dec 2024) to 30.70%, marking an increase of 6.23%.
- For Other Income, as of Mar 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Dec 2024) to 0.04 Cr., marking an increase of 0.03 Cr..
- For Interest, as of Mar 2025, the value is 0.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.69 Cr. (Dec 2024) to 0.58 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Mar 2025, the value is 1.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.68 Cr. (Dec 2024) to 1.70 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Dec 2024) to 1.26 Cr., marking an increase of 1.08 Cr..
- For Tax %, as of Mar 2025, the value is 26.98%. The value appears to be improving (decreasing) as expected. It has decreased from 44.44% (Dec 2024) to 26.98%, marking a decrease of 17.46%.
- For Net Profit, as of Mar 2025, the value is 0.92 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Dec 2024) to 0.92 Cr., marking an increase of 0.81 Cr..
- For EPS in Rs, as of Mar 2025, the value is 1.32. The value appears strong and on an upward trend. It has increased from 0.16 (Dec 2024) to 1.32, marking an increase of 1.16.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.16 | 24.45 | 25.10 | 28.63 | 30.40 | 33.74 | 28.16 | 25.69 | 30.04 | 34.44 | 36.70 | 41.78 | 42.28 |
| Expenses | 17.85 | 19.30 | 19.95 | 23.85 | 24.06 | 26.48 | 24.62 | 21.57 | 21.14 | 24.17 | 26.42 | 30.48 | 30.98 |
| Operating Profit | 4.31 | 5.15 | 5.15 | 4.78 | 6.34 | 7.26 | 3.54 | 4.12 | 8.90 | 10.27 | 10.28 | 11.30 | 11.30 |
| OPM % | 19.45% | 21.06% | 20.52% | 16.70% | 20.86% | 21.52% | 12.57% | 16.04% | 29.63% | 29.82% | 28.01% | 27.05% | 26.73% |
| Other Income | 0.10 | 0.63 | -0.05 | 0.86 | 0.35 | 0.25 | -2.80 | 0.49 | 0.12 | 2.47 | 0.16 | 0.07 | 0.06 |
| Interest | 1.19 | 1.57 | 1.23 | 1.47 | 1.59 | 1.54 | 1.89 | 2.82 | 3.23 | 3.52 | 3.06 | 2.72 | 2.53 |
| Depreciation | 1.59 | 2.83 | 2.73 | 2.86 | 3.16 | 3.68 | 4.56 | 4.60 | 5.43 | 5.50 | 5.71 | 6.50 | 6.67 |
| Profit before tax | 1.63 | 1.38 | 1.14 | 1.31 | 1.94 | 2.29 | -5.71 | -2.81 | 0.36 | 3.72 | 1.67 | 2.15 | 2.16 |
| Tax % | 28.83% | 36.23% | 36.84% | 32.06% | 29.90% | 30.13% | -32.05% | -7.12% | 44.44% | 13.71% | 32.93% | 29.30% | |
| Net Profit | 1.17 | 0.88 | 0.72 | 0.89 | 1.35 | 1.60 | -3.88 | -2.61 | 0.21 | 3.21 | 1.11 | 1.52 | 1.50 |
| EPS in Rs | 1.68 | 1.26 | 1.03 | 1.28 | 1.94 | 2.30 | -5.57 | -3.75 | 0.30 | 4.61 | 1.59 | 2.18 | 2.15 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -24.79% | -18.18% | 23.61% | 51.69% | 18.52% | -342.50% | 32.73% | 108.05% | 1428.57% | -65.42% | 36.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | 6.60% | 41.79% | 28.07% | -33.17% | -361.02% | 375.23% | 75.31% | 1320.53% | -1493.99% | 102.36% |
Choksi Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 12% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 32% |
| 3 Years: | 93% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 83% |
| 3 Years: | 86% |
| 1 Year: | 175% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 7% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| Reserves | 13.35 | 12.35 | 13.07 | 14.16 | 15.43 | 17.04 | 13.26 | 10.78 | 10.94 | 14.14 | 15.25 | 16.64 | 17.53 |
| Borrowings | 11.45 | 11.65 | 13.68 | 11.20 | 12.43 | 17.05 | 31.64 | 39.15 | 37.29 | 32.41 | 30.87 | 29.15 | 28.87 |
| Other Liabilities | 6.93 | 6.70 | 8.81 | 8.32 | 9.85 | 14.28 | 13.14 | 9.48 | 9.22 | 6.84 | 8.86 | 12.57 | 11.87 |
| Total Liabilities | 38.70 | 37.67 | 42.53 | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 | 65.24 |
| Fixed Assets | 23.98 | 19.28 | 17.64 | 22.23 | 28.62 | 34.81 | 33.08 | 50.32 | 46.56 | 44.83 | 43.43 | 47.61 | 45.83 |
| CWIP | 2.23 | 2.73 | 8.99 | 4.28 | 0.00 | 3.23 | 13.06 | 0.50 | 1.67 | 0.31 | 2.99 | 0.00 | 0.48 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 12.49 | 15.66 | 15.90 | 14.14 | 16.06 | 17.30 | 18.87 | 15.56 | 16.19 | 15.22 | 15.53 | 17.72 | 18.93 |
| Total Assets | 38.70 | 37.67 | 42.53 | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 | 65.24 |
Below is a detailed analysis of the balance sheet data for Choksi Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.97 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.97 Cr..
- For Reserves, as of Sep 2025, the value is 17.53 Cr.. The value appears strong and on an upward trend. It has increased from 16.64 Cr. (Mar 2025) to 17.53 Cr., marking an increase of 0.89 Cr..
- For Borrowings, as of Sep 2025, the value is 28.87 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 29.15 Cr. (Mar 2025) to 28.87 Cr., marking a decrease of 0.28 Cr..
- For Other Liabilities, as of Sep 2025, the value is 11.87 Cr.. The value appears to be improving (decreasing). It has decreased from 12.57 Cr. (Mar 2025) to 11.87 Cr., marking a decrease of 0.70 Cr..
- For Total Liabilities, as of Sep 2025, the value is 65.24 Cr.. The value appears to be improving (decreasing). It has decreased from 65.33 Cr. (Mar 2025) to 65.24 Cr., marking a decrease of 0.09 Cr..
- For Fixed Assets, as of Sep 2025, the value is 45.83 Cr.. The value appears to be declining and may need further review. It has decreased from 47.61 Cr. (Mar 2025) to 45.83 Cr., marking a decrease of 1.78 Cr..
- For CWIP, as of Sep 2025, the value is 0.48 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.48 Cr., marking an increase of 0.48 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 18.93 Cr.. The value appears strong and on an upward trend. It has increased from 17.72 Cr. (Mar 2025) to 18.93 Cr., marking an increase of 1.21 Cr..
- For Total Assets, as of Sep 2025, the value is 65.24 Cr.. The value appears to be declining and may need further review. It has decreased from 65.33 Cr. (Mar 2025) to 65.24 Cr., marking a decrease of 0.09 Cr..
However, the Borrowings (28.87 Cr.) are higher than the Reserves (17.53 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.14 | -6.50 | -8.53 | -6.42 | -6.09 | -9.79 | -28.10 | -35.03 | -28.39 | -22.14 | -20.59 | -17.85 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 117.27 | 126.15 | 124.77 | 112.19 | 118.62 | 95.09 | 90.60 | 115.94 | 125.03 | 112.87 | 103.33 | 98.46 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 28.27 | 30.50 | 37.89 | 20.28 | 15.62 | 46.09 | 34.68 | 51.33 | 65.94 |
| Days Payable | 591.13 | 594.31 | 660.70 | 723.24 | 685.97 | 741.06 | 297.29 | 560.33 | 639.34 | |||
| Cash Conversion Cycle | 117.27 | 126.15 | 124.77 | -450.67 | -445.18 | -527.72 | -612.36 | -554.41 | -569.95 | -149.73 | -405.67 | -474.95 |
| Working Capital Days | 8.73 | 29.26 | 3.34 | -23.71 | -18.37 | 28.02 | 21.13 | -49.73 | -23.33 | 11.66 | -49.13 | -71.29 |
| ROCE % | 9.25% | 7.94% | 7.51% | 7.33% | 10.51% | 10.09% | -1.48% | 0.00% | 6.40% | 9.16% | 8.87% | 9.20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.19 | 1.59 | 4.61 | 0.30 | -3.74 |
| Diluted EPS (Rs.) | 2.19 | 1.59 | 4.61 | 0.30 | -3.74 |
| Cash EPS (Rs.) | 11.52 | 9.80 | 12.50 | 8.09 | 2.86 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 |
| Revenue From Operations / Share (Rs.) | 59.99 | 52.68 | 49.45 | 43.13 | 36.88 |
| PBDIT / Share (Rs.) | 16.23 | 14.90 | 15.01 | 12.93 | 6.62 |
| PBIT / Share (Rs.) | 6.89 | 6.70 | 7.12 | 5.13 | 0.01 |
| PBT / Share (Rs.) | 3.09 | 2.39 | 5.34 | 0.52 | -4.03 |
| Net Profit / Share (Rs.) | 2.19 | 1.59 | 4.61 | 0.29 | -3.74 |
| PBDIT Margin (%) | 27.04 | 28.29 | 30.35 | 29.97 | 17.95 |
| PBIT Margin (%) | 11.49 | 12.72 | 14.39 | 11.90 | 0.03 |
| PBT Margin (%) | 5.15 | 4.53 | 10.80 | 1.22 | -10.93 |
| Net Profit Margin (%) | 3.64 | 3.02 | 9.32 | 0.68 | -10.15 |
| Return on Networth / Equity (%) | 6.45 | 4.99 | 15.20 | 1.15 | -14.69 |
| Return on Capital Employeed (%) | 11.58 | 10.83 | 10.36 | 7.31 | 0.02 |
| Return On Assets (%) | 2.33 | 1.79 | 5.31 | 0.32 | -3.92 |
| Long Term Debt / Equity (X) | 0.64 | 0.81 | 1.12 | 1.54 | 1.77 |
| Total Debt / Equity (X) | 1.19 | 1.32 | 1.44 | 1.94 | 1.91 |
| Asset Turnover Ratio (%) | 0.65 | 0.59 | 0.55 | 0.45 | 0.39 |
| Current Ratio (X) | 0.68 | 0.77 | 1.11 | 0.90 | 0.80 |
| Quick Ratio (X) | 0.66 | 0.75 | 1.10 | 0.88 | 0.79 |
| Inventory Turnover Ratio (X) | 90.75 | 8.94 | 9.63 | 10.95 | 17.75 |
| Interest Coverage Ratio (X) | 4.27 | 3.45 | 2.99 | 2.81 | 1.64 |
| Interest Coverage Ratio (Post Tax) (X) | 1.57 | 1.37 | 1.27 | 1.06 | 0.07 |
| Enterprise Value (Cr.) | 111.15 | 58.14 | 53.31 | 52.04 | 39.01 |
| EV / Net Operating Revenue (X) | 2.66 | 1.58 | 1.55 | 1.73 | 1.52 |
| EV / EBITDA (X) | 9.84 | 5.60 | 5.10 | 5.78 | 8.46 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 0.80 | 0.67 | 0.58 | 0.21 |
| Price / BV (X) | 3.55 | 1.33 | 1.10 | 0.98 | 0.30 |
| Price / Net Operating Revenue (X) | 2.00 | 0.80 | 0.67 | 0.58 | 0.21 |
| EarningsYield | 0.01 | 0.03 | 0.13 | 0.01 | -0.47 |
After reviewing the key financial ratios for Choksi Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.52. This value is within the healthy range. It has increased from 9.80 (Mar 24) to 11.52, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 59.99. It has increased from 52.68 (Mar 24) to 59.99, marking an increase of 7.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 16.23. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 16.23, marking an increase of 1.33.
- For PBIT / Share (Rs.), as of Mar 25, the value is 6.89. This value is within the healthy range. It has increased from 6.70 (Mar 24) to 6.89, marking an increase of 0.19.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.09. This value is within the healthy range. It has increased from 2.39 (Mar 24) to 3.09, marking an increase of 0.70.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.19. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For PBDIT Margin (%), as of Mar 25, the value is 27.04. This value is within the healthy range. It has decreased from 28.29 (Mar 24) to 27.04, marking a decrease of 1.25.
- For PBIT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has decreased from 12.72 (Mar 24) to 11.49, marking a decrease of 1.23.
- For PBT Margin (%), as of Mar 25, the value is 5.15. This value is below the healthy minimum of 10. It has increased from 4.53 (Mar 24) to 5.15, marking an increase of 0.62.
- For Net Profit Margin (%), as of Mar 25, the value is 3.64. This value is below the healthy minimum of 5. It has increased from 3.02 (Mar 24) to 3.64, marking an increase of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.45. This value is below the healthy minimum of 15. It has increased from 4.99 (Mar 24) to 6.45, marking an increase of 1.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.58. This value is within the healthy range. It has increased from 10.83 (Mar 24) to 11.58, marking an increase of 0.75.
- For Return On Assets (%), as of Mar 25, the value is 2.33. This value is below the healthy minimum of 5. It has increased from 1.79 (Mar 24) to 2.33, marking an increase of 0.54.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.64, marking a decrease of 0.17.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has decreased from 1.32 (Mar 24) to 1.19, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has increased from 0.59 (Mar 24) to 0.65, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1.5. It has decreased from 0.77 (Mar 24) to 0.68, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.66, marking a decrease of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 90.75. This value exceeds the healthy maximum of 8. It has increased from 8.94 (Mar 24) to 90.75, marking an increase of 81.81.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.27. This value is within the healthy range. It has increased from 3.45 (Mar 24) to 4.27, marking an increase of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 3. It has increased from 1.37 (Mar 24) to 1.57, marking an increase of 0.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 111.15. It has increased from 58.14 (Mar 24) to 111.15, marking an increase of 53.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.66, marking an increase of 1.08.
- For EV / EBITDA (X), as of Mar 25, the value is 9.84. This value is within the healthy range. It has increased from 5.60 (Mar 24) to 9.84, marking an increase of 4.24.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
- For Price / BV (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 3.55, marking an increase of 2.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Choksi Laboratories Ltd:
- Net Profit Margin: 3.64%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.58% (Industry Average ROCE: 17.2%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.45% (Industry Average ROE: 13.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.66
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 47.1 (Industry average Stock P/E: 41.35)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.64%
Choksi Laboratories Ltd: Intrinsic Value & Share Price Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Survey No 9/1, Near Tulsiyana Industrial Park, Indore Madhya Pradesh 452010 | compliance_officer@choksilab.com http://www.choksilab.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sunil Kumar Choksi | Managing Director |
| Mrs. Stela Choksi | Whole Time Director |
| Ms. Himika Choksi | Whole Time Director |
| Mr. Vyangesh Choksi | Whole Time Director |
| Mr. Raghmendra Singh | Independent Director |
| Mrs. Meenaxi Patidar | Independent Director |
| Mrs. Prachi Mantri | Independent Director |
| Mrs. Abha Shastri | Independent Director |
FAQ
What is the intrinsic value of Choksi Laboratories Ltd?
Choksi Laboratories Ltd's intrinsic value (as of 09 December 2025) is 89.69 which is 19.92% lower the current market price of 112.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 78.2 Cr. market cap, FY2025-2026 high/low of 237/60.2, reserves of ₹17.53 Cr, and liabilities of 65.24 Cr.
What is the Market Cap of Choksi Laboratories Ltd?
The Market Cap of Choksi Laboratories Ltd is 78.2 Cr..
What is the current Stock Price of Choksi Laboratories Ltd as on 09 December 2025?
The current stock price of Choksi Laboratories Ltd as on 09 December 2025 is 112.
What is the High / Low of Choksi Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Choksi Laboratories Ltd stocks is 237/60.2.
What is the Stock P/E of Choksi Laboratories Ltd?
The Stock P/E of Choksi Laboratories Ltd is 47.1.
What is the Book Value of Choksi Laboratories Ltd?
The Book Value of Choksi Laboratories Ltd is 35.2.
What is the Dividend Yield of Choksi Laboratories Ltd?
The Dividend Yield of Choksi Laboratories Ltd is 0.00 %.
What is the ROCE of Choksi Laboratories Ltd?
The ROCE of Choksi Laboratories Ltd is 9.20 %.
What is the ROE of Choksi Laboratories Ltd?
The ROE of Choksi Laboratories Ltd is 6.63 %.
What is the Face Value of Choksi Laboratories Ltd?
The Face Value of Choksi Laboratories Ltd is 10.0.